Recorded fact · drug.label_indication

drug.label_indication for selexipag|pulmonary-arterial-hypertension

One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact 41095bb9 resolves to.

The record

Fact id	`41095bb9333954e55e21aae9`
Entity	drug: selexipag\|pulmonary-arterial-hypertension
Field	drug.label_indication
Source	api.fda.gov
Read on	2026-11-10T19:02:47.536Z
Source version	openfda-label-20260528
Method	extract
Verification	verified
Licence	CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels
Edition	2026-11, Merkle root `006ab9a329709cbe...`

The verifying quote

UPTRAVI is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I): In adults to delay disease progression and reduce the risk of hospitalization for PAH.

Shown with dashes as hyphens. SHA-256 of the exact stored quote: ab5e4dc8e768743641a3c5a8cd5155b355fa1407b45bcea8a48596cb2a37a02a.

The value

{
 "ingredient": "Selexipag",
 "conditionId": "pulmonary-arterial-hypertension",
 "conditionName": "Pulmonary Arterial Hypertension",
 "matchedAlias": "pulmonary arterial hypertension",
 "context": "indication",
 "brand": "UPTRAVI",
 "identifiedVia": "generic_name",
 "extractor": 5,
 "labelSetId": "a7a23b87-f892-4e2c-8e2e-ebf841220f90",
 "labelEffectiveTime": "20260528",
 "labelsRead": 1,
 "labelsNaming": 1,
 "registryEditionRoot": "1b44e76f5da1a417",
 "meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}

SHA-256 of the exact stored value: 03ae8af42f434fc0b18dd2767dec5f91e40eafa9f266d8caffb9eb372d9c69b0.

This fact as data (JSON) · Check an answer against its receipt · Licence

Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.